Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
Asian patients with type 2 diabetes (T2D) are younger, leaner, and more likely to develop renal dysfunction than White populations. In this multiethnic analysis of data from phase 3 trials, we investigated the efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in Asians stratified by these subphenotypes. Data from randomized, double-blind, placebo-controlled trials evaluating linagliptin (as monotherapy, add-on therapy to metformin ± sulfonylurea, combined with pioglitazone or added to insulin) were pooled with efficacy data from 11 randomized trials of at least 24 weeks and safety data from 15 trials of various durations. In the efficacy set, 1404 Asian patients received linagliptin [mean (standard deviation) age 54.5 (10.1) years; body mass index (BMI) 26.0 (3.9) kg/m 2 ] and 661 received placebo [age 55.0 (9.7) years; BMI 26.1 (3.9) kg/m 2 ] with the same glycated hemoglobin (HbA1c): 8.2 (0.9)% in both groups. At 24 weeks, the placebo-corrected adjusted mean ± standard error change from baseline in HbA1c with linagliptin was −0.73 ± 0.04% (95% confidence interval −0.81, −0.65; P < 0.0001). Reductions in HbA1c were similar upon stratification by age [<65 years, −0.71 ± 0.05% (−0.80, −0.62; P < 0.0001); ≥65 years, −0.81 ± 0.10% (−1.01, −0.60; P < 0.0001)], BMI (<25 kg/m 2 , −0.82 ± 0.06% [−0.94, −0.70; P < 0.0001]; ≥25 kg/m 2 , −0.65 ± 0.06% [−0.76, −0.54; P < 0.0001]) and estimated glomerular filtration rate [<90 mL/min/1.73 m 2 , −0.71 ± 0.06% (−0.82, −0.60; P < 0.0001); ≥90 mL/min/1.73 m 2 , −0.75 ± 0.06% (−0.87, −0.64; P < 0.0001)]. In the safety set (linagliptin, n = 1842; placebo, n = 839), 52.2% and 54.6% of patients, respectively, experienced adverse events. The rates of drug-related adverse events were 10.9% in the linagliptin group and 10.4% in the placebo group. The respective rates of hypoglycemia were 8.3% and 9.5%, mainly among patients treated with sulfonylurea or insulin. Severe hypoglycemia was rare (<1.0% in either group). Linagliptin effectively reduced hyperglycemia in Asian patients with uncontrolled T2D, irrespective of age, BMI, renal function, or ethnic subgroups, and was well tolerated. Boehringer Ingelheim, Eli Lilly and Company, and the Diabetes Alliance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DPP-4 inhibitors do not have significant GI adverse effects and may be used in early combination with metformin.1038–1043”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1040]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the VERIFY trial,1040 initial combination therapy of metformin and the DPP-4 inhibitor vildagliptin was superior to sequential addition of medications in prolonging the occurrence of primary and secondary failure.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1040]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Global estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642 · cited 2×
“Asia has experienced a marked rise in the prevalence of type 2 diabetes (T2D) in recent years [1, 2].”
BackgroundDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“DPP-4 inhibitors augment prandial insulin secretion and suppress glucagon with low risk of hypoglycemia [21].”
BackgroundDiabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology
Chan, J. C. N., Malik, V., Jia, W., Kadowaki, T., Yajnik, C. S., Yoon, K.-H., & Hu, F. B. (2009) · JAMA · doi:10.1001/jama.2009.726 · Cited by 1,997 · cited 4×
“, hypoglycemia, weight gain) may be particularly relevant to Asian patients with T2D [3].”
BackgroundInfluentialSelf-citationRamachandran, A., Wan Ma, R. C., & Snehalatha, C. (2010) · The Lancet · doi:10.1016/s0140-6736(09)60937-5 · Cited by 782
Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea
Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020735 · Cited by 649
Self-citationEthnic Differences in the Relationship Between Insulin Sensitivity and Insulin Response
Kodama, K., Tojjar, D., Yamada, S., Toda, K., Patel, C. J., & Butte, A. J. (2013) · Diabetes Care · doi:10.2337/dc12-1235 · Cited by 599 · cited 1×
“In a multiethnic population, Asian individuals had a lower insulinogenic index than White populations, which might contribute to the high prevalence of T2D in Asian populations [27].”
BackgroundDipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525 · cited 1×
“Dipeptidyl peptidase-4 (DPP-4) inhibitors prolong the half-life of the incretin hormone, glucagon-like peptide-1 (GLP1), which augments prandial insulin secretion and suppresses glucagon secretion [8].”
BackgroundKim, Y. G., Hahn, S., Oh, T. J., Kwak, S. H., Park, K. S., & Cho, Y. M. (2013) · Diabetologia · doi:10.1007/s00125-012-2827-3 · Cited by 396
Lanting, L. C., Joung, I. M. A., Mackenbach, J. P., Lamberts, S. W. J., & Bootsma, A. H. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2280 · Cited by 386 · cited 1×
“Early age of diagnosis and therefore long disease duration as well as high risk for renal dysfunction in Asian T2D patients may have implications for the selection of antidiabetes drugs [3, 5, 6, 19, 20].”
Background
Research works printed but not linked: 2
- American Diabetes Association. Standards of medical care in diabetes—2015: summary of revisions. Diabetes Care. 2015;38(Suppl):S4.
- Bajaj M, Gilman R, Patel S, Kempthorne-Rawson J, Woerle HJ. Linagliptin improved glycemic control without weight gain or hypoglycemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone. Diabetes. 2013;62(Suppl 1):A283.
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Chadha, M. D., Das, A. K., Deb, P., Gangopadhyay, K. K., Joshi, S., Kesavadev, J., KOVIL, R. R., Kumar, S., Misra, A., & Mohan, V. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01219-x · Cited by 60
“In another study, linagliptin effectively reduced hyperglycemia in Asian patients with uncontrolled T2DM, irrespective of age, body mass index, renal function, or ethnic subgroup, and was well tolerated [34].”
BackgroundHanif, W., Ali, S. N., Bellary, S., Patel, V., Farooqi, A., Karamat, M. A., Saeed, M. A., Sivaprasad, S., Patel, K., & Khunti, K. (2020) · Diabetic Medicine · doi:10.1111/dme.14497 · Cited by 25
Jain, A., Vispute, A., Dange, A., Naskar, A., Mondal, A., Vivekanand, B., Sharma, B., Varade, D., Shukla, D., Bhatia, G., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01504-3 · Cited by 14
Yamamoto, F., Unno, Y., Okamura, T., Ikeda, R., Ochiai, K., & Hayashi, N. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00723-x · Cited by 10
Metadata
- Authors
- Ning, G., Bandgar, T., Hehnke, U., Lee, J., & Chan, J. C. N.
- Affiliations
- King Edward Memorial Hospital and Seth G.S. Medical College (IN)
- Boehringer Ingelheim (Germany) (DE)
- Chinese University of Hong Kong (HK)
- Corresponding author
- Ning, Guang
- Venue
- Advances in Therapy
- Published
- 2017-08-17
- Volume
- 34
- Issue
- 9
- Pages
- 2150-2162
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- PMC
- PMC5599450
- OpenAlex
- W2750537112
- Cited by
- 13
- References
- 48
- Citations by year
- 2025: 1 · 2023: 2 · 2022: 4 · 2021: 2 · 2020: 3 · 2019: 1
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Advances in Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- Diabetes Alliance
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- linagliptin, type 2 diabetes, DPP-4 inhibitors, Asian patients, age, obesity, renal function, HbA1c reduction, glycemic control, renal safety, drug safety, metformin, sulfonylureas, pioglitazone, insulin, subgroup analysis, pooled analysis of trials, renal dysfunction, older adults, body mass index
- MeSH terms
- Linagliptin, Adult, Age Factors, Aged, Aged, 80 and over, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Asian People, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials. https://app.cochat.ai/papers/10.1007/s12325-017-0595-7
- The paper
- Ning, G., Bandgar, T., Hehnke, U., Lee, J., & Chan, J. C. N. (2017). Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials. Advances in Therapy. https://doi.org/10.1007/s12325-017-0595-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.